Lacosamide (Vimpat, UCB) appears both cost- and utility-effective as an add-on therapy for adults with uncontrolled partial-onset seizure, according to a pharmacoeconomics analysis that was recently presented at the International Society for Pharmacoeconomics Research.
Lacosamide (Vimpat, UCB) appears both cost- and utility-effective as an add-on therapy for adults with uncontrolled partial-onset seizure, according to a pharmacoeconomics analyses that was recently presented at the International Society for Pharmacoeconomics Research.
Lacosamide was FDA approved in 2008 as an adjunctive therapy for the treatment of partial-onset seizures in patients aged 17 years and older with epilepsy. Lacosamide became available in the United States in May 2009 as tablet and intravenous formulations. In 2010, lacosamide was approved as an oral solution.
The study included more than 5 years of published safety and efficacy data from 2 pivotal, multinational, clinical trials supporting long-term use of lacosamide. Researchers used a simulated pharmacoeconomic model to analyze standard antiepileptic drug therapy with and without lacosamide as add-on therapy in a hypothetical cohort of 1,000 adults with uncontrolled partial onset seizures from the third-party payer perspective in the United States. Standard cost- and utility-effectiveness ratios were calculated based on 2 years of therapy compared with five other standard therapies: carbamazepine, lamotrigine, levetiracetam, topiramate, and valproate.
The analysis found that treatment with lacosamide was associated with an incremental gain of 6,730 avoided seizures and 38 quality-adjusted life years (QALY), an estimated $223 to $733 saved per seizure, and an estimated $39,574 per QALY gained.
In addition, the willingness-to-pay threshold ($50,000 per QALY) for lacosamide was met in 77% of patient simulations after 2 years of treatment.
“Cost- and utility-effectiveness analyses help to quantify the economic rationale for a treatment, which is an important factor in evaluating the use of a potential therapy,” said Hicham Benhaddi, senior health economist at UCB in a press release issued by the company. “These findings provide additional support for lacosamide’s utility as an antiepileptic drug in the reimbursement community, and among healthcare professionals and patients.”
ICER Identifies 5 Drugs with Unsupported Price Increases
December 12th 2024The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and Xeljanz — with prices increases that are not supported by new clinical evidence, with a total of $815 million in added costs to U.S. payers in 2023.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More